H

Hospital Clinico Universitario de Valencia | Nephrology Department

Research site
(Unclaimed)
Location
10 Blasco Ibanez Avenue 2nd floor, Hemodyalisi Unit, Valencia, Valencia, Spain

Site insights

Top conditions

Top treatments

Trastuzumab
Carboplatin
Paclitaxel
Palbociclib
Risankizumab
Docetaxel
Nivolumab
Veliparib
Lenalidomide
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

44 of 94 total trials
Locations recently updated

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head...

Enrolling
Squamous Cell Carcinoma of the Head and Neck
Drug: Tiragolumab
Drug: Carboplatin

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Sotorasib
Drug: Pembrolizumab

This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It wi...

Active, not recruiting
Carcinoma, Non-Small- Cell Lung
Melanoma
Drug: carboplatin
Drug: pembrolizumab

The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (AL...

Enrolling
B Cell Precursor Acute Lymphoblastic Leukemia
Drug: Blinatumomab
Locations recently updated

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Enrolling
HER2 Positive Breast Cancer
Drug: Pertuzumab
Drug: Trastuzumab

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specifi...

Enrolling
HER2-positive Breast Cancer
Drug: T-DM1
Drug: tucatinib

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor,...

Enrolling
Non Small Cell Lung Cancer
Drug: Docetaxel
Biological: Telisotuzumab Vedotin

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of th...

Enrolling
Non-Hodgkin Lymphoma
Drug: Prednisone
Drug: Lenalidomide

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Rituximab

To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: Leramistat
Drug: Placebo

The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202) in patients with previously treated RAS mutant advanced...

Enrolling
Metastatic Colon Cancer
Colorectal Cancer
Drug: FOLFIRI regimen
Drug: Ompenaclid (RGX-202)

This is a prospective, multicenter, single arm, window-of-opportunity study evaluating the biological effect of U3-1402 in treatment naïve patients w...

Active, not recruiting
Breast Cancer
Drug: U3 1402

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment i...

Active, not recruiting
Breast Cancer Stage II
Breast Cancer Stage III
Drug: doxorubicin/cyclophosphamide
Drug: Docetaxel / cyclophosphamide

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Enrolling
Anemia
Myelofibrosis
Other: Placebo
Drug: ACE-536

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The...

Active, not recruiting
Uterine Cervical Neoplasms
Uterine Neoplasms
Drug: fulvestrant
Drug: trastuzumab

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Enrolling
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Other: Placebo
Drug: Nivolumab

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

Trial sponsors

AbbVie logo
Amgen logo
Genmab logo
M
Seagen logo
E
Celgene logo
S
Allergan logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems